Caspase-1 as a radio- and chemo-sensitiser in vitro and in vivo.

The cytotoxic effect of anticancer drugs has been shown to involve induction of apoptosis. This observation raises the possibility that factors affecting caspase activation might be important determinants of anticancer drug sensitivity. Ectopic expression of caspase-1 has been shown to trigger apoptosis. However, the role of caspase-1 in apoptosis is now considered as minor compared to other caspases. In patients, high levels of caspase-1 expression may be associated with spontaneous regression in neuroblastomas and with a good clinical response to chemotherapy in acute myeloid leukemia and osteosarcoma. In experimental therapeutics for cancer, caspase-1 has been related to some anticancer activity. These observations led us to examine the effect of over-expression on the response to chemotherapy and radiotherapy in vitro and in vivo. Caspase-1 expression mediated by an adenoviral vector was able to kill directly cells and to sensitise the remaining cells to cisplatin or gamma-radiation in vitro. In HeLa cells stably transfected with caspase-1, sensitisation to cisplatin was due to an amplification of the cisplatin-induced mitochondrial apoptotic pathway activation. Caspase-1 mediated sensitisation to cisplatin and gamma-radiation was also observed in vivo. Altogether, we conclude that caspase-1 can act as a radio- and chemo-sensitiser, in vitro and in vivo.

[1]  G. Vassaux,et al.  Direct comparison of the insulating properties of two genetic elements in an adenoviral vector containing two different expression cassettes. , 2004, Human gene therapy.

[2]  Shai Shaham,et al.  Death without caspases, caspases without death. , 2004, Trends in cell biology.

[3]  B. Ng,et al.  Fibroblast Growth Factor 2-Mediated Translational Control of IAPs Blocks Mitochondrial Release of Smac/DIABLO and Apoptosis in Small Cell Lung Cancer Cells , 2003, Molecular and Cellular Biology.

[4]  D. Khayat,et al.  Serum caspase-1 levels in metastatic melanoma patients: relationship with tumour burden and non-response to biochemotherapy , 2002, Melanoma research.

[5]  Martin A. Koschat,et al.  Serum concentrations of APO-1/Fas and interleukin-1beta-converting enzyme in osteosarcoma correlate with response to chemotherapy. , 2002, Anticancer research.

[6]  H. Miyake,et al.  Over expression of inhibitor of caspase 3 activated deoxyribonuclease in human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy in vivo. , 2001, The Journal of urology.

[7]  S. Kaufmann,et al.  Apoptosis and the response to anticancer therapy , 2001, Current opinion in oncology.

[8]  S. Gansauge,et al.  Overexpression of Caspase-1 (Interleukin-1&bgr; Converting Enzyme) in Chronic Pancreatitis and Its Participation in Apoptosis and Proliferation , 2001, Pancreas.

[9]  I. McNeish,et al.  Herpes simplex virus thymidine kinase/ganciclovir–induced cell death is enhanced by co-expression of caspase-3 in ovarian carcinoma cells , 2001, Cancer Gene Therapy.

[10]  B. Foster,et al.  Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer. , 2001, Cancer research.

[11]  A. Borkowski,et al.  Human Prostate Cancer Loss of Caspase-1 and Caspase-3 Protein Expression in Updated Version , 2001 .

[12]  W. Earnshaw,et al.  Induction of apoptosis by cancer chemotherapy. , 2000, Experimental cell research.

[13]  Z. Kolár̂,et al.  The expression of apoptosis-related proteins and the apoptotic rate in glial tumors of the brain. , 2000, Neoplasma.

[14]  Y. Minagawa,et al.  Cisplatin‐resistant HeLa Cells Are Resistant to Apoptosis via p53‐dependent and ‐independent Pathways , 1999, Japanese journal of cancer research : Gann.

[15]  S. Ramón y. Cajal,et al.  In vivo radiosensitizing effect of the adenovirus E1A gene in murine and human malignant tumors. , 1999, International journal of oncology.

[16]  I. Ferrer,et al.  Role of caspases in ionizing radiation-induced apoptosis in the developing cerebellum. , 1999, Journal of neurobiology.

[17]  D. Mahvi,et al.  Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  F. Schröder,et al.  Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. , 1999, European journal of cancer.

[19]  D. Kirsch,et al.  Tumor-suppressor p53: implications for tumor development and prognosis. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Suzuki,et al.  Necessity of interleukin-1beta converting enzyme cascade in taxotere-initiated death signaling. , 1998, European journal of pharmacology.

[21]  K. Kinzler,et al.  A simplified system for generating recombinant adenoviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  I. Herr,et al.  Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). , 1997, Blood.

[23]  M. Su,et al.  Interleukin-1 beta converting enzyme (ICE) is preferentially expressed in neuroblastomas with favourable prognosis. , 1997, European journal of cancer.

[24]  X. Breakefield,et al.  Retroviral delivery and tetracycline-dependent expression of IL-1beta-converting enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumor cells. , 1996, Cancer research.

[25]  M. Miura,et al.  Activation of an interleukin 1 converting enzyme-dependent apoptosis pathway by granzyme B. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  W. Wilmanns,et al.  Association of bcl-2, bax, bcl-xL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. , 1996, Leukemia.